新冠疫情期间羟氯喹的精神不良反应。
Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.
机构信息
CMHS, United Arab Emirates University, Department of psychiatry and behavioural sciences, Al Ain, United Arab Emirates.
CMHS, United Arab Emirates University, Department of psychiatry and behavioural sciences, Al Ain, United Arab Emirates.
出版信息
Asian J Psychiatr. 2020 Dec;54:102203. doi: 10.1016/j.ajp.2020.102203. Epub 2020 Jun 20.
Abstract
• HCQ, well known in rheumatology, dermatology and tropical medicine is now considered in the treatment and prophylaxy for the SARS-CoVid19. • Mental and neurological manifestations should be assessed following the use of hydrochloroquine particularly following prophylactic use. • For acute malaria studies, HCQ was associated with high prevalenceof mental neurological manifestations amongst anti-malaria drugs. • Recommendations of using HCQ in COVID are variable and sometimes contradictory depending on agencies and countries.
摘要
• 在风湿病学、皮肤病学和热带医学领域广为人知的羟氯喹，现在被认为可用于治疗和预防 SARS-CoVid19。• 使用羟氯喹后，特别是预防性使用后，应评估精神和神经表现。• 在急性疟疾研究中，羟氯喹与抗疟药物中精神神经表现的高患病率有关。• 各机构和国家对羟氯喹在 COVID 中的使用的建议各不相同，有时甚至相互矛盾。
相似文献
1
Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.新冠疫情期间羟氯喹的精神不良反应。
Asian J Psychiatr. 2020 Dec;54:102203. doi: 10.1016/j.ajp.2020.102203. Epub 2020 Jun 20.
2
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.精神障碍与羟氯喹治疗 2019 年冠状病毒病（COVID-19）：一项 VigiBase 研究。
Drug Saf. 2020 Dec;43(12):1315-1322. doi: 10.1007/s40264-020-01013-3. Epub 2020 Oct 19.
3
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.经验性使用羟氯喹治疗疑似新型冠状病毒肺炎诱发急性泛发性脓疱性皮疹。
Dermatol Ther. 2020 Nov;33(6):e13834. doi: 10.1111/dth.13834. Epub 2020 Jul 8.
4
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.在 SARS-CoV-2（COVID-19）紧急情况下预防耳毒性。
J Glob Antimicrob Resist. 2020 Dec;23:263-264. doi: 10.1016/j.jgar.2020.09.030. Epub 2020 Oct 17.
5
Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.新冠病毒病患者中羟氯喹诱发的多形红斑
Med Clin (Barc). 2020 Sep 11;155(5):231. doi: 10.1016/j.medcli.2020.05.004. Epub 2020 May 19.
6
Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir.新型冠状病毒肺炎治疗药物的视网膜毒性评估：羟氯喹和洛匹那韦/利托那韦
J Med Virol. 2021 Feb;93(2):644-646. doi: 10.1002/jmv.26420. Epub 2020 Sep 28.
7
The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19.羟氯喹和氯喹在 COVID-19 中的兴衰。
J Pharm Pract. 2022 Dec;35(6):971-978. doi: 10.1177/0897190021997399. Epub 2021 Apr 28.
8
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.新冠病毒疾病（COVID-19）患者使用羟氯喹的精神科影响
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
9
A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?1例新型冠状病毒肺炎患者在使用奥司他韦和羟氯喹后银屑病加重：新型冠状病毒肺炎大流行后银屑病病例会增加吗？
Dermatol Ther. 2020 Jul;33(4):e13383. doi: 10.1111/dth.13383. Epub 2020 Apr 24.
10
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
引用本文的文献
1
Psychotropics and COVID-19: An analysis of safety and prophylaxis.精神药物与 COVID-19：安全性与预防分析。
Encephale. 2021 Dec;47(6):564-588. doi: 10.1016/j.encep.2021.08.002. Epub 2021 Sep 2.
2
The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19.新型冠状病毒肺炎恢复期三种证型及六种中成药的研究
Chin Med. 2021 Jun 7;16(1):44. doi: 10.1186/s13020-021-00454-x.
3
Disaster management of the psychological impact of the COVID-19 pandemic.2019冠状病毒病疫情心理影响的灾害管理
Int J Emerg Med. 2021 Mar 24;14(1):19. doi: 10.1186/s12245-021-00342-z.
4
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.关于COVID-19治疗方案的系统评价：药物疗效的临床证据及启示
Infect Drug Resist. 2020 Dec 29;13:4673-4695. doi: 10.2147/IDR.S289037. eCollection 2020.
本文引用的文献
1
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
2
RETRACTED: Chinese mental health burden during the COVID-19 pandemic.撤回：COVID-19 大流行期间的中国精神卫生负担。
Asian J Psychiatr. 2020 Jun;51:102052. doi: 10.1016/j.ajp.2020.102052. Epub 2020 Apr 14.
3
The COVID-19 pandemic, personal reflections on editorial responsibility.新冠疫情：关于编辑责任的个人思考
Asian J Psychiatr. 2020 Apr;50:102100. doi: 10.1016/j.ajp.2020.102100. Epub 2020 Apr 18.
4
Decolonising COVID-19.使新冠疫情去殖民化
Lancet Glob Health. 2020 May;8(5):e612. doi: 10.1016/S2214-109X(20)30134-0.
5
Pakistanis' mental health during the COVID-19.新冠疫情期间巴基斯坦人的心理健康状况
Asian J Psychiatr. 2020 Jun;51:102127. doi: 10.1016/j.ajp.2020.102127. Epub 2020 Apr 23.
6
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.氯喹和羟氯喹在非洲预防或治疗 COVID-19：医疗环境中不适当的超说明书使用需谨慎。
Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188. doi: 10.4269/ajtmh.20-0290.
7
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.氯喹的神经精神不良事件：使用 FDA 不良事件报告系统（FAERS）数据库的真实世界药物警戒研究。
Biosci Trends. 2020 May 21;14(2):139-143. doi: 10.5582/bst.2020.03082. Epub 2020 Apr 22.
8
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.印度针对新冠病毒病接触者的羟氯喹预防措施
Lancet Infect Dis. 2020 Oct;20(10):1118-1119. doi: 10.1016/S1473-3099(20)30313-3. Epub 2020 Apr 17.
9
COVID-19 and mental health: A review of the existing literature.新型冠状病毒肺炎（COVID-19）与心理健康：现有文献综述。
Asian J Psychiatr. 2020 Aug;52:102066. doi: 10.1016/j.ajp.2020.102066. Epub 2020 Apr 10.
10
Issues relevant to mental health promotion in frontline health care providers managing quarantined/isolated COVID19 patients.在管理新冠病毒隔离/检疫患者的一线医护人员中与促进心理健康相关的问题。
Asian J Psychiatr. 2020 Jun;51:102084. doi: 10.1016/j.ajp.2020.102084. Epub 2020 Apr 7.
Zotero 插件